Compare Medpace Holdings Inc (MEDP) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Xcel Energy Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Xcel Energy Inc trades at $73.78 (market cap $45.82B). The key difference: Xcel Energy Inc is far larger — about 2.7× Medpace Holdings Inc's market cap, and Xcel Energy Inc pays a 3.23% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Xcel Energy Inc for 61 Days on average.
| MEDP | XEL | |
|---|---|---|
Market Cap | $16.82B | $45.82B |
Volume | 223,093 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $630.19 | $83.91 |
52-Week Low | $393.42 | $69.39 |
Typical Hold Time | 14 Days | 61 Days |
Enterprise Value | $16.44B | $84.14B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Xcel Energy (XEL) trades at $73.36, up 1.3% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent earnings beats. Recent news highlights growth from data center power demand and a $60B capital investment plan. Technical indicators show bullish momentum with support at $72-73 and resistance at $74-75 levels.
XEL presents a compelling investment case with analyst consensus target of $90.83 (24% upside) and 63% buy ratings. Key opportunities include infrastructure expansion and rising power demand, while risks involve wildfire liabilities and high capital expenditure. The stock's valuation at 20.1 P/E appears reasonable given growth prospects and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
